Table 2 Scores of SF-36 between antiviral-treated CHC patients, Taiwanese general populations, and patients without antiviral therapy
SF-36 domains & CLDQ | General populations (N = 256,A) mean (SD) | CHC without antiviral-treated patients (N = 64,B) Mean (SD) | Antiviral-treated CHC patients (N = 64,C) Mean (SD) | F¸ (post-hoc multiple comparison) t-test |
|---|---|---|---|---|
Physical functioning | 82.79 (22.16) | 71.95 (29.33) | 75.86 (21.85) | 6.57** (A > B) |
Role physical | 72.95 (41.34) | 66.07 (45.36) | 35.94 (44.29) | 19.19** (A > C&B > C) |
Bodily pain | 74.26 (17.97) | 80.63 (25.04) | 73.30 (22.84) | 2.88 |
General health | 64.78 (19.96) | 41.84 (28.57) | 51.78 (20.99) | 32.35** (A > C > B) |
Vitality | 65.33 (16.80) | 60.94 (25.91) | 50.00 (25.09) | 15.01**(A,B > C) |
Social functioning | 83.35 (15.98) | 81.53 (22.49) | 75.23 (24.39) | 4.78**(A > C) |
Role emotional | 79.43 (37.72) | 78.11 (37.70) | 43.20 (46.66) | 22.32** (A,B > C) |
Mental health | 70.91 (14.77) | 71.88 (18.43) | 61.00 (20.51) | 10.10** (A,B > C) |
PCS | 48.39 (8.52) | 52.97 (17.20) | 40.78 (12.50) | 20.06** (B > A > C) |
MCS | 49.73 (8.19) | 49.73 (12.00) | 46.34 (12.51) | 3.23* (A > C) |
Abdominal symptom | Â | 6.06 (1.30) | 5.75(1.33) | 1.31 |
Fatigue | Â | 5.38(1.56) | 4.78(1.38) | 2.31* |
Systemic symptoms | Â | 5.71(1.09) | 4.98(1.06) | 3.88** |
Activity | Â | 5.12(1.51) | 5.21(1.52) | 1.01 |
Emotional function | Â | 5.78(1.16) | 5.02(1.42) | 3.30** |
Worry | Â | 6.10(1.33) | 5.95(1.16) | 0.71 |